Faron Pharmaceuticals Oy (FRA:4FR) (H1 2026) Earnings Call Highlights: Bexmarilimab Shows 45% CR Rate in High-Risk MDS, Paving the Way for Pivotal Phase IIb Trial
· gurufocus.com
Release Date: August 26, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Faron Pharmace
Release Date: August 26, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Faron Phar...